#None #Infant Health #RSV Vaccination #UKHSA

Maternal RSV Vaccination: A Game Changer for Infant Health

A major study presented at the ESCMID Global 2026 conference has provided compelling evidence regarding the benefits of maternal vaccination against respiratory syncytial virus (RSV). This investigation, recognized as the largest real-world study to date, reveals that administering the RSV vaccine to pregnant women significantly lessens the risk of hospitalisation for their infants, achieving a reduction of over 80% when the vaccine is administered at least two weeks prior to birth.

Respiratory syncytial virus is a prevalent cause of severe respiratory ailments in infants and young children. The virus can lead to serious conditions such as bronchiolitis and pneumonia, making it one of the leading causes of infant hospitalisation globally. Previous studies have highlighted long-term consequences of early RSV infections, linking them to ongoing respiratory issues such as recurrent wheeze and asthma, repeat hospital admissions, and impaired lung health.

To tackle this public health concern, the UK government initiated a national maternal RSV vaccination program on September 1, 2024. This program offers the Bivalent Prefusion F vaccine to pregnant women starting from 28 weeks' gestation. The primary aim was to evaluate the vaccine's effectiveness in reducing infant hospitalisations due to RSV-related lower respiratory tract infections (LRTIs).

Conducted by the UK Health Security Agency (UKHSA), researchers utilized linked national datasets, which encompassed NHS maternity records, vaccination data, as well as hospital and laboratory records. The dataset involved 289,399 infants born between September 2, 2024, and March 24, 2025, comprising around 90% of all births in England during that time frame.

The findings of the study were striking. A total of 4,594 RSV-associated hospitalisations were documented among the infant population studied. Interestingly, despite unvaccinated mothers making up 55% of the cohort, their infants accounted for a staggering 87.2% of all hospitalisations. Conversely, infants whose mothers received the vaccine at least 14 days prior to delivery showed a significant reduction in hospitalisation risk, with the vaccine's effectiveness estimated at an impressive 81.3% compared to the unvaccinated group.

Matt Wilson, the lead author and an epidemiologist with the UKHSA, expressed the importance of these findings: “This study serves as the largest investigation into the impact of RSV vaccination on infant hospitalisation. The evidence strongly supports the notion that vaccination provides substantial safeguards against severe illness in young infants.” He further noted a clear correlation between the timing of vaccination and protective effectiveness: the longer the interval between the vaccination and birth, the higher the protection, reaching nearly 85% when administered four weeks or more before delivery.

The study also turned its focus on preterm infants, estimated to have a vaccine effectiveness of 69.4% provided that there is at least a 14-day gap between vaccination and birth. Wilson emphasized that this aspect is especially crucial for preterm infants, who are the most susceptible to severe RSV infections. “With adequate time between vaccination and delivery,” he stated, “we observed considerable levels of protection in these newborns.”

Overall, these remarkable findings underscore the vital role of maternal RSV vaccination in safeguarding the health of infants. As the research continues to unfold, public health officials are hopeful that increasing awareness and uptake of this vaccination will contribute significantly to reducing RSV-related hospitalisations and improving long-term health outcomes for infants across the globe.